Related Experiment Video
Updated: Mar 22, 2026
11:38
Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
Published on: July 3, 2014
47.6K
Summary
Early-stage breast cancer patients identified by genomic testing may not need adjuvant chemotherapy. This finding from the MINDACT trial aims to reduce unnecessary treatment and associated long-term side effects.
Area of Science:
- Oncology
- Genomics
- Clinical Trials
Background:
- The MINDACT trial is a prospective, randomized phase III study.
- Investigated the role of genomic profiling in early-stage breast cancer treatment decisions.
Discussion:
- Adjuvant chemotherapy offers survival benefits but carries risks of significant long-term side effects.
- Unnecessary chemotherapy exposes patients to risks like cardiac toxicity, secondary cancers, and early menopause.
Key Insights:
- Genomic testing can identify a subset of early-stage breast cancer patients who can safely avoid adjuvant chemotherapy.
- Results support a personalized medicine approach, tailoring treatment to individual tumor biology.
Outlook:
- Potential to change clinical practice by reducing overtreatment in early-stage breast cancer.
- Future research may further refine criteria for chemotherapy de-escalation based on genomic signatures.
More Related Videos
13:43Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
Published on: April 1, 2022
5.0K
12:57X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
Published on: December 9, 2022
2.8K
